

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



November 11, 2025

Company Takara Bio Inc. (Securities code: 4974;
Prime Market)
Headquarters Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
Representative Tsuyoshi Miyamura, President & CEO
Contact Noritaka Nishiwaki, Executive Officer, in
charge of PR & IR Department
Telephone (+81)77-565-6970
Website <https://www.takara-bio.co.jp/>

Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (No dividends) and Partial Return of Executive Remuneration

Takara Bio Inc. (the “Company”) hereby announces that in the light of the most recent operating trends, it has revised the financial results forecasts for the fiscal year ending March 31, 2026 (April 1, 2025 – March 31, 2026) and the year-end dividend forecasts for the year ending March 31, 2026, disclosed on May 13, 2025, as described below. Furthermore, the Company has decided to waive a portion of executive remuneration.

1. Revisions to financial results forecasts

(1) Revisions to consolidated financial results forecasts for the full year of the current fiscal year (April 1, 2025 through March 31, 2026)

	Net sales	Operating profit	Ordinary profit	Net income attributable to owners of the parent	Net income per share
	Million yen	Million yen	Million yen	Million yen	Yen
Previously announced forecasts (A) (Disclosed on May 13, 2025)	52,500	2,500	2,500	1,300	10 08
Revised forecasts (B)	42,100	(4,000)	(4,400)	(9,000)	(78 06)
Change (B-A)	(10,400)	(6,500)	(6,900)	(10,300)	-
Change (%)	(19.8)	-	-	-	-
(Reference) Actual consolidated results for the previous fiscal year (Fiscal year ended March 31, 2025)	45,039	2,263	2,592	1,041	8 65

(2) Reason for revision

For the second half of the current fiscal year, the global life sciences research market is expected to remain sluggish. In Japan, factors such as the shortfall in acquiring new projects in the CDMO business are also having an impact. As a result, net sales are expected to fall below the previously announced forecast. Despite efforts to review personnel structure, prioritize R&D activities, and reduce SG&A expenses, the significant impact of decline in sales is anticipated result in both operating profit and ordinary profit falling below the previously announced forecast. Furthermore, due to the recognition of extraordinary losses and the partial reversal of deferred tax assets announced on October 23, 2025, net income attributable to owners of the parent is expected to fall below the previously announced forecast for full fiscal year period.

For details of the forecasts announced this time, please refer to the “Comparative Statement of Income Relating to Consolidated Financial Forecasts” on page 11 of the “Consolidated Financial Results for the Six Months Ended September 30, 2025” announced today.

2. Revisions to dividend forecasts

(1) Details of revision

	Annual dividends (Yen)		
	Second quarter-end	Fiscal-year end	Total
Previous forecasts (Disclosed on May 13, 2025)		17.00	17.00
Revised forecasts		00.00	00.00
Actual results for the current fiscal year	0.00		
Actual results for the previous fiscal year (Fiscal year ended March 31, 2025)	0.00	17.00	17.00

(2) Reason for revision

The Company considers returning profits to shareholders to be an important management issue, while paying attention to enhancing internal reserves in order to actively implement R&D activities in both Bioindustry and Gene Therapy businesses. The basic policy of the Company is to return profits to shareholders based on a comprehensive consideration of its operating results and financial position. Specifically, the Company's policy is to pay dividends from retained earnings on the basis of 35% of the estimated net income, which is calculated without taking into account extraordinary gains and losses in the consolidated financial statements. With respect to dividend payments, the Company aims to promote management that focuses on market valuation, and therefore considers both its consolidated full-year financial forecasts and overall management policies in a comprehensive manner.

However, in light of the anticipated significant net loss for the current fiscal year, and after careful deliberation, the Company has regretfully decided not to issue a year-end dividend.

3. Voluntary Return of Executive Remuneration

Given the anticipated significant net loss and the decision to forgo dividend payments, the Company sincerely acknowledges the circumstances and has decided to voluntarily return a portion of executive remuneration as outlined below to clearly demonstrate its commitment to management responsibility.

(1) Details of Voluntary Return of Executive Remuneration

Chairman, President & CEO : 30% of monthly remuneration

Director & Vice President : 25% of monthly remuneration

Senior Managing Executive Officer : 20% of monthly remuneration

Senior Executive Officer : 15% of monthly remuneration

Executive Officer : 10% of monthly remuneration

(2) Reduction Period of Executive Remuneration

November 2025 to March 2026 (5 months' worth)

Forward-Looking Statements

Statements contained in these materials with respect to the Company's current plans, forecasts, strategies and beliefs that are not historical facts are forward-looking statements about the further performance of the Company and its consolidated subsidiaries. These statements are based on management's assumptions and beliefs in light of information currently available to it, but are based on a number of assumptions and beliefs derived from information that contains significant risks and uncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.